Joining forces to harness the full potential of therapies for life-threatening diseases

"At Celyad, we believe that working together with pharma partners will help us ensuring a global access of patients to the therapies we develop. To achieve this goal, we will carefully consider how the combined strengths of such partnerships will allow us to go faster and further than each alone". 
Georges Rawadi - VP Business Development & IP at Celyad


Partnerships are key to fuel our quest to innovative products that will enhance our pipeline, but also to identify the right commercial partners that will help us develop and commercialize our drug candidates. Based on our experience, we understand the creativity and challenges it takes to translate innovation into products. Celyad is looking to consider all opportunities with a strong scientific rationale in the field of immune-therapy regardless of the development stage.

Latest News

Celyad enters into license agreement with ONO PHARMACEUTICAL CO., LTD. to develop allogeneic NKR-2 T-cell immunotherapy

Celyad enters into license agreement with ONO PHARMACEUTICAL CO., LTD. to develop allogeneic NKR-2 T-cell immunotherapy

Celyad announces collaboration with Institut Curie for the development of its immuno-oncology program NKR-T

Celyad announces collaboration with Institut Curie for the development of its immuno-oncology program NKR-T

Celyad retains Piper Jaffray & Co. to explore strategic alternatives relating to its C-Cure® cardiovascular assets

Celyad retains Piper Jaffray & Co. to explore strategic alternatives relating to its C-Cure® cardiovascular assets

Discover all news

Our areas of interest

Want to see more?

Our areas of interest